Meeting
2023 ASCO Annual Meeting
Safety, efficacy, and biomarker analysis of response to engineered tumor-infiltrating lymphocytes secreting anti-PD-1 antibody in recurrent glioblastoma: An open-label, two-arms, phase 1 study.
Authors
Yu Yao
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
Yu Yao , Di Chen , Chao Tang , Chunxia Ji , Zhong Li , Qijun Qian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03347097
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2042)
DOI
10.1200/JCO.2023.41.16_suppl.2042
Abstract #
2042
Poster Bd #
399
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
First Author: David A. Reardon
Poster
2024 ASCO Breakthrough
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma.
First Author: Ruofan Huang
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2023 ASCO Annual Meeting
Lisavanbulin (BAL101553), a novel, oral microtubule destabilizer plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma: A phase 1 Adult Brain Tumor Consortium study (ABTC1601).
First Author: Matthias Holdhoff